These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18398099)

  • 21. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of recurrent small cell lung cancer.
    Davies AM; Evans WK; Mackay JA; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Apr; 18(2):387-416. PubMed ID: 15094178
    [No Abstract]   [Full Text] [Related]  

  • 23. High-dose chemotherapy in nonseminomatous germ cell cancer.
    Kollmannsberger C; Beyer J; Bokemeyer C
    BJU Int; 2009 Nov; 104(9 Pt B):1398-403. PubMed ID: 19840020
    [No Abstract]   [Full Text] [Related]  

  • 24. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Which chemotherapy for diffuse forms of small-cell cancers?].
    Pujol JL; Quantin X; Carestia L; Guyot V; Khial F
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S149-55. PubMed ID: 10088297
    [No Abstract]   [Full Text] [Related]  

  • 26. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
    You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
    Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group.
    Hatton MQ; Cassidy J; Bicknell S; Semple P; Stack B; Steward WP
    Eur J Cancer; 1995 Jun; 31A(6):1022-3. PubMed ID: 7646904
    [No Abstract]   [Full Text] [Related]  

  • 28. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
    Socinski MA
    J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy for elderly SCLC patients.
    Satoh H; Ohtsuka M; Sekizawa K
    Lung Cancer; 2003 Apr; 40(1):107. PubMed ID: 12660016
    [No Abstract]   [Full Text] [Related]  

  • 30. Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be not better.
    Sasse AD; Lima JP; Sasse EC; Santos LV
    J Clin Oncol; 2009 Dec; 27(35):e253; author reply e254. PubMed ID: 19884522
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse B; Le Chevalier T
    J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of small cell carcinoma of the lung.
    Foley JF; Peterson WC; Mailliard JA
    Nebr Med J; 1989 Nov; 74(11):330-2. PubMed ID: 2555729
    [No Abstract]   [Full Text] [Related]  

  • 33. Commentary on "carboplatin-etoposide association in small cell lung cancer patients older than 70 years: a phase II trial".
    Murray N
    Lung Cancer; 2002 Jan; 35(1):9-10. PubMed ID: 11750706
    [No Abstract]   [Full Text] [Related]  

  • 34. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome.
    Julious SA; Campbell MJ; Walker SJ; George SL; Machin D
    Br J Cancer; 2000 Oct; 83(7):959-63. PubMed ID: 10970702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ifosfamide].
    Manegold C
    Zentralbl Gynakol; 1996; 118(10):580-1. PubMed ID: 8999718
    [No Abstract]   [Full Text] [Related]  

  • 37. [The Cleopatra project].
    Lotz JP; Lecesne A; Trillet-Lenoir V
    Rev Pneumol Clin; 1999 Sep; 55(4):234-5. PubMed ID: 10573755
    [No Abstract]   [Full Text] [Related]  

  • 38. Hypopharyngeal small cell carcinoma: a case report.
    Sano M; Kitahara N; Toma M
    Auris Nasus Larynx; 2005 Sep; 32(3):319-22. PubMed ID: 15927428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
    Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
    Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.